Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Zhang, Tian, Pabla, Sarabjot, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Giamo, Vincent, Andreas, Jonathan, Wang, Yirong, Bshara, Wiam, Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Gupta, Rajan, Zhu, Jason, Labriola, Matthew, McCall, Shannon, George, Daniel J., Ghatalia, Pooja, Dayyani, Farshid, Edwards, Robert, Park, Michelle S, Singh, Rajbir, Jacob, Robin, George, Saby, Xu, Bo, Zibelman, Matthew, Kurzrock, Razelle, Morrison, Carl
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458647/
https://ncbi.nlm.nih.gov/pubmed/32923131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1773200
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares